#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Loss of consciousness Congenital absence of bile ducts Diabetes insipidus Endocrine ophthalmopathy Stargardt's disease Cholangiosarcoma Duchenne muscular dystrophy Nephrotic syndrome Encephalitis autoimmune Neurotrophic keratopathy Obesity Metachromatic leukodystrophy Testicular leiomyosarcoma Myelin oligodendrocyte glycoprotein antibody-associated disease Polycystic liver disease More trials…

    Learn about Rare Diseases

    Pleomorphic leiomyosarcoma – Life with Disease Familial amyotrophic lateral sclerosis – Treatment Gaucher’s disease type III – Trials in Disease Osteosarcoma Synovial sarcoma metastatic – Life with Disease Waldenstrom’s macroglobulinaemia – Life with Disease Mucous membrane pemphigoid – Trials in Disease Hereditary hypophosphataemic rickets – Life with Disease Prolymphocytic leukaemia – Basic Information Pemphigus More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    POTASSIUM HYDROXIDE Englumafusp Alfa Dermatophagoides Farinae Xanthum Gum Zamtocabtagene Autoleucel Dolutegravir Emtricitabine Upacicalcet Sodium Hydrate Samuraciclib Ads-015 Volixibat Amsacrine Ambrisentan LUXDEGALUTAMIDE Epoetin Alfa Alfacalcidol Amantadine Hydrochloride Sepiapterin Danicamtiv Pentoxifylline More therapies…

    Learn about Your Condition

    Cardiac amyloidosis Oesophageal atresia Papillary thyroid cancer Toxic epidermal necrolysis Gingival bleeding Cardiac failure Foetal growth restriction Cardiovascular disorder Alcoholic liver disease Hypopituitarism Latent tuberculosis Breast cancer recurrent Sarcoidosis Basal cell carcinoma Acute lymphocytic leukaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Uniwersytecki Szpital Kliniczny Im.Fryderyka Chopina…

Uniwersytecki Szpital Kliniczny Im.Fryderyka Chopina W Rzeszowie

Ul. Fryderyka Szopena 2, Rzeszow, 35-055, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Apremilast
    • Envudeucitinib
    Austria Estonia France Germany Hungary Latvia +3

  • Study Comparing CT-P55 and Secukinumab for Moderate to Severe Plaque Psoriasis Patients

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Secukinumab
    Poland

  • Study on the Effect of Pancreatic Enzyme Replacement Therapy with Pancreas Powder in Patients with Pancreatic Exocrine Insufficiency After Total Gastrectomy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Pancreatic failure
    Investigated Drugs:
    • Pancreas Powder
    Poland Portugal Spain

  • Study on the Effectiveness and Safety of Brensocatib for Adults with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    2 1
    Investigated Drugs:
    • BRENSOCATIB
    Bulgaria France Germany Greece The Netherlands Poland +1

  • Study on the Effectiveness of LY4100511 for Adults with Moderate-to-Severe Plaque Psoriasis

    Not recruiting

    2 1
    Investigated Drugs:
    • Ly4100511
    Czechia Germany Hungary Poland

  • Study on Long-term Safety and Effectiveness of Zasocitinib for Patients with Moderate-to-Severe Plaque Psoriasis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Zasocitinib
    Bulgaria Czechia France Germany Hungary Italy +3

  • Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

    Not recruiting

    3 1
    Investigated Diseases:
    • Neurodermatitis
    Investigated Drugs:
    • 4-[3-(Cyanomethyl)-3-(3′,5′-Dimethyl-1H,1’H-[4,4′-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
    Belgium Czechia Germany Poland Spain

  • Study on Long-term Effects of Secukinumab in Patients with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Secukinumab
    Austria Belgium Bulgaria Croatia Czechia Greece +8

  • Study of dupilumab effectiveness compared to placebo in adults with bullous pemphigoid

    Not recruiting

    4 1 1
    Investigated Diseases:
    • Pemphigoid
    Investigated Drugs:
    • Betamethasone Sodium Phosphate
    • Dupilumab
    France Germany Poland Spain

  • Study on Long-Term Safety and Effectiveness of Bimekizumab for Adults with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Bimekizumab
    Bulgaria France Germany Greece Ireland Italy +3
Previous Page
1 … 3 4 5 6 7 … 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!